Effectiveness of Ustekinumab Dose Escalation in Patients with Crohn ’s Disease

A subset of patients with Crohn ’s disease (CD) do not respond to ustekinumab at the standard dose of 90 mg every 8 weeks. Little is known about the efficacy of shortening the interval between doses.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research